Novel farnesoid X receptor agonists (FXR), peroxisome proliferator-activated receptor (PPAR) agonists, and fibroblast growth factor 19 (FGF19) analogs are in development and may act as second-line therapy for primary biliary cholangitis refractory to UDCA. Here, FGF19 is linked to biliary liver cirrhosis.